112257-12-2

Usage

Uses

4-(Bromoacetyl)-1-Boc-piperazine is an inhibitor of transglutaminase.

Upstream product

• 598-21-0 2-Bromoacetyl bromide 
• 57260-71-6 1-t-Butoxycarbonylpiperazine 
• 79-08-3 bromoacetic acid 
• 497-19-8 sodium carbonate 
• 24424-99-5 di-tert-butyl dicarbonate 
• 861359-74-2 diisopropylethyl amine 

Downstream Products

• 890153-36-3 1-triphenylphosphoranylidenemethylcarbonyl-4-tert-butoxycarbonyl-piperazine 
• 1360467-58-8 4-methylbenzenesulfinic acid 1,1,3,3-tetramethylguanidine salt 
• 1289636-05-0 tert-butyl 4-(2-diazoacetyl)piperazine-1-carboxylate 

Relevant academic research and scientific papers

A ruthenium(ii) complex-cyanine energy transfer scaffold based luminescence probe for ratiometric detection and imaging of mitochondrial peroxynitrite

A novel ruthenium(ii) complex-cyanine energy transfer scaffold has been established for the development of a ratiometric luminescence probe for ONOO- detection. The probe, Ru-Cy5, is localized in mitochondria of live cells, allowing ratiometric sensing and imaging of ONOO- therein.

FRET-Based Mito-Specific Fluorescent Probe for Ratiometric Detection and Imaging of Endogenous Peroxynitrite: Dyad of Cy3 and Cy5

Peroxynitrite (OONO-) is profoundly implicated in health and disease. The physiological and pathological outcome of OONO- is related to its local concentration, and hence, a reliable OONO- assay is highly desired. We have developed a FRET-based small-molecule fluorescent probe (PNCy3Cy5), harnessing the differential reactivity of Cy3 and Cy5 toward OONO- by fine-tuning. It exhibits high detection sensitivity and yields a ratiometric fluorescent signal. We have exemplified that it can be applied in semiquantitative determination of OONO- in living cells. Notably, it specifically localizes in mitochondria, where endogenous OONO- is predominantly generated. Thus, PNCy3Cy5 is a promising molecular tool for peroxynitrite biology.

UDP GLYCOSYLTRANSFERASE INHIBITORS AND METHODS OF USE

Described herein is a compound of Formula (I), and pharmaceutically acceptable salts thereof. Also described herein are compositions and the use of such compositions in methods of treating a variety of diseases and conditions, in particular Krabbe's Disease (KD) and Metachromatic leukodystrophy (MLD).

Compound with fluorescence resonance energy transfer performance and its application

The invention relates to a compound with fluorescence resonance energy transfer performance and its application. The compound is prepared by trimethine cyanine dye and pentamethine cyanine dye througha proper connecting arm. The compound provided by the invention can be applied to detect active oxygen and active nitrogen, and is not influenced by probe concentration, background fluorescence, instrumental error and other factors; moreover, the compound has relatively high FRET efficiency.

FUSED RING HETEROARYL COMPOUNDS AND THEIR USE AS TRK INHIBITORS

The disclosure provides novel chemical compounds represented by Formula I or a pharmaceutically acceptable salt, solvate, polymorph, ester, tautomer or prodrug thereof. The compounds can be used as an inhibitor of Trk and are useful in the treatment of pain, cancer, inflammation, neurodegenerative disease and certain infectious diseases. In some compounds of Formula I, Q is —CH═CR3C(O)NR4R5, —C≡CC(O)NR4R5, or

FLUORINATED LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF

Described herein are compounds that are LOXL2 inhibitors, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with LOXL2 activity.

Oxazolidinone-quinolone hybrid antibiotics

The present invention relates to compounds of the Formula (I) that are useful antimicrobial agents and effective against a variety of multi-drug resistant bacteria:

ACYLPIPERAZINES AS INHIBITORS OF TRANSGLUTAMINASE AND THEIR USE IN MEDICINE

The present invention relates to novel compounds of Formula I capable of inhibiting tissue transglutaminase, and uses of the same in medicine. In particular, the invention provides compounds for use in the treatment of prevention of disease and conditions such as fibrosis (e.g. cystic fibrosis), scarring, neurodegenerative diseases (e.g. Alzheimer's disease, Huntington's disease and Parkinson's disease), autoimmune diseases (e.g. multiple sclerosis and coeliac disease), thrombosis, proliferative disorders (e.g. cancers), AIDS, psoriasis and inflammation (e.g. chronic inflammatory diseases).

α-Bromodiazoacetamides - a new class of diazo compounds for catalyst-free, ambient temperature intramolecular C-H insertion reactions

In this work, we introduce a new class of halodiazocarbonyl compounds, α-halodiazoacetamides, which through a metal-free, ambient-temperature thermolysis perform intramolecular C-H insertions to produce α-halo-β-lactams. When carried out with α-bromodiazoacetamides bearing cyclic side chains, the thermolysis reaction affords bicyclic α-halo-β-lactams, in some cases in excellent yields, depending on the ring size and substitution pattern of the cyclic amide side chains.

New Potent Bisubstrate Inhibitors of Histone Acetyltransferase p300: Design, Synthesis and Biological Evaluation

Bisubstrate-type compound Lys-CoA has been shown to inhibit the p300 histone acetyl transferase activity efficiently and may constitute a lead compound for a novel class of anticancer therapeutics. Based on this strategy, we synthesized a series of CoA derivatives and evaluated these molecules for their activity as p300 histone acetyltransferases inhibitor. The best activity was obtained with compound 3 bearing a C-5 spacing linker that connects the CoA moiety to a tert-butyloxycarbonyl (Boc) group. Based on docking simulations, this inhibitor exhibits favorable interactions with two binding areas, namely pockets P1 and P2, within the active site.